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Ερευνητικό άρθρο
ABSTRACT: Cardiac side effect of 5-hydroxytryptamine-3 receptor antagonists has been a concern for clinicians. 
There is a substantial need for greater clarity about the safety of granisetron hydrochloride, an antiemetic agent of this 
class used in oncological and parvoviral gastroenteritis with acute vomiting in dogs.This study aimed to assess the elec-
trocardiographic effects of a single dose of intravenous granisetron. We randomly assigned 16 adult crossbreed female 
healthy dogs into two groups of intervention and control and injected them intravenously with granisetron and normal 
saline, respectively, at a dose of 0.5 ml/kg over one minute. Standard electrocardiography (ECG) was recorded at the 
baseline, as well as 5, 15, 30, 60, 120, 360, and 720 minutes after the intervention. Heart rate and ECG parameters (PR 
intervals, QRS duration, ST-segment, T-wave amplitudes, QT, JT, QTc and JTc intervals) were evaluated in lead II.No 
significant difference was observed between the intervention and the control groups in any of the measured variables 
at any of the time-points. Mean values of measured parameters showed no significant difference compared with base-
line values in the control group, while the granisetron group saw statistically significant but clinically asymptomatic 
changes in heart rate, PR, QRS, QT, JT, and QTc at different time-points, compared to the baseline values (P<0.05). In 
conclusion, Granisetron administration was not associated with clinically significant adverse effects on ECG variables 
or heart rate. Thus, it can be regarded as a relatively safe drug.
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INTRODUCTION
Nausea and vomiting are among the commonly encountered side effects in patients undergoing 
chemotherapy, occurring in most cytostatic chemo-
therapeutic regimens among cancer patients (Harris 
2010; Janelsins et al. 2013; Schnell 2003; Yamakuni 
et al. 2000).Moreover, severe gastroenteritis especial-
ly in puppies with parvoviral infection can be a major 
cause of nausea and vomiting in animals (Goddard and 
Leisewitz 2010; Nandi and Kumar 2010; Woods et al. 
1980). These emesis occurring within 24 hours, is 
now known to be mediated via 5-hydroxythriptamin3 
(5-HT3) receptors and thus can be controlled with the 
specific 5-HT3 receptor antagonists (Grunberg 1993; 
Hsu 2010). Granisetron, ondansetron, andtropisetron, 
having been considered the most powerful antiemet-
ics so far, have been proven at least equally effica-
cious as conventional treatments (Chevallier 1993; 
Gomez-de-Segura et al. 1998; Gregory and Ettinger 
1998; Hsu 2010; Janelsins et al. 2013; Schnell 2003).
5-HT3 receptor antagonists, however, have been re-
portedly associated with an increased risk of abnormali-
ties in cardiac repolarization. For instance, some studies 
have reported adverse electrocardiographic effects from 
granisetron and raised concerns over the possibility of this 
drug causing arrhythmia (Buyukavci et al. 2005; Pınarlı 
et al. 2006). Previous studies have stated that efficacy 
of 5-HT3 receptor antagonists when used intravenously 
outweighs their risk and small, transient electrocardio-
graphic abnormalities that might appear are clinically in-
significant (Cakir et al. 2012; Coop 2003; Ghaffari et al. 
2010; Keefe 2002; Navari and Koeller 2003).
However, available evidence is not sufficient to war-
rant their safety, especially in patients with preexisting 
cardiovascular disorders or those receiving cardiotoxic 
drugs e.g. chemotherapeutic regimens. Potential cardio-
vascular adverse effects of 5-HT3 receptor antagonists 
have attracted growing research interest and studies have 
investigated the safety of some of these agents. Never-
theless, an interventional animal study to evaluate the 
electrocardiographic effects of granisetron and its safe-
ty compared with placebois lacking (Dennis et al. 2007; 
Ghaffari et al. 2010; Tricco et al. 2016). Therefore, the 
present study was aimed to assess the electrocardio-
graphic effects of single-dose intravenous administration 
of granisetron on healthy dogs, as animal models.
MATERIALS AND METHODS
Study Design
The "The first evaluation of the electrocardio-
graphic effects of iv granisetron (As hydrochloride) 
3 mg (Caspian Tamin, Iran) in healthy dogs» was an 
experimental, randomized, placebo-controlled study. 
The study was approved by the Iran Society for Pre-
vention of Cruelty to Animals in accordance with Ira-
nian ethical codes for studies on laboratory animals. 
The contract between the sponsor (Ferdowsi Univer-
sity of Mashhad) and the guide investigator provided 
that the latter would have full access to all results and 
the right to independently publish the study regardless 
of the outcome.
Animals
In this experimental study, 16 adult crossbreed fe-
male dogs with a mean weight of 23.32±0.78 kg were 
included. The study was performed completely ac-
cording to the principles of the World Medical Associ-
ation (WMA) statement on animal use in biomedical 
research. For a period of two weeks before the inter-
vention, all included dogs were housed individually 
in cages in an animal room with standard and moni-
tored conditions for environmental adaptation. Water 
and commercial dry dog foods were given to the dogs 
ad libitum during the study. The dogs were vaccinated 
and antiparasitic agents were given to them.
All dogs underwent thorough physical examination, 
blood and fecal analysis before the study and standard 
electrocardiography at the baseline and their condition 
were confirmed as healthy based on the results. 
Exclusion criteria: Dogs were excluded from the 
study if they had cardiovascular disease and clinically 
relevant systemic disease. 
We removed the dogs from their home cages and 
took them to a quiet room two hoursbeforethe interven-
tion so that they can acclimatize to the environment.
The dogs were randomly assigned to two differ-
ent groups of intervention (N=8) and control (N=8). 
The intervention group received intravenous granis-
etron,injected slowly at a dose of 0.5 ml/kg over one 
minute, while the control group received intravenous 
normal saline at the exact same dose and condition.
A 6-lead standard electrocardiogram (ECG)
comprising leads I, II, III, aVR, aVL, and aVF was 
performed using a single channel digital electrocar-
diograph (ECG 110, Kenzo®, Suzuken, Japan) and 
recorded at 50 mm/s and 10 mm/mv for all dogs, 
while they were in right lateral recumbency position 
on a table. All ECGs were performed by one single 
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expert operator observing the standard conditions.
One-minute ECGs of lead II were recorded in all 
dogs at baseline and 5, 15, 30, 60, 120, 360, and 720 
minutes after the intervention. In all ECGs taken, heart 
rate, PR interval, QRS duration, ST segment, T-wave 
amplitude, QT interval, and JT interval were recorded 
in checklists for each dog. The JT interval was cal-
culated by subtracting QRS duration from the QT in-
terval, measured from the endpoint of QRS complex 
(known as j-point) to the endpoint of T wave, marking 
the point that T wave returns to the isoelectric line. 
Moreover, we calculated the rate-corrected QT and JT 
intervals, being known as QTc and JTc, respectively, 
using the formulas below.
Statistical Methods
Statistical analysis was performed using the statis-
tical package for social sciences (SPSS; version 12.0 
for Windows, IBM Statistics, Chicago, IL, USA). 
One-sample Kolmogorov-Smirnov test was used to 
assess the normal distribution of data. Independent 
samples t-test was used to compare the measured pa-
rameters in each time-point between the two groups. 
Paired samples t-test was used to compare data with 
the baseline values in each group. P<0.05 was consid-
ered as statistically significant.
RESULTS
Overall, 16 dogs in two groups of intervention 
(N=8) and control (N=8) were studied. The electrocar-
diographic parameters of dogs in both groups are shown 
in Table-1. As the table implies, in the control group, 
none of the measured parameters changed significantly 
at any of the time-points, compared with their baseline 
values. However, in the intervention group, several pa-
rameters were changed significantly at different time-
points, compared with baseline values.
Mean heart rate of the intervention group was sig-
nificantly different from their baseline heart rate 30, 
60, and 120 minutes after the intervention (P=0.033, 
P=0,033, and P=0.015, respectively). In the interven-
tion group, mean QRS duration 5 minutes after the in-
tervention and mean QTc interval 15 minutes after the 
intervention was significantly different from the cor-
responding baseline values (P=0.011 and P=0.037).
Moreover, mean values of PR, QT, and JT intervals 5, 
15, 30, 60, 120, and 360 minutes after the intervention 
was significantly different from the baseline value in 
the intervention group (P<0.05). Nevertheless, mean 
values of ST segment, JTc interval, and T wave am-
plitude had no significant change over the course of 
study in the intervention group.
Table 1. Mean values of electrocardiographic parameters in intervention and control groups at different time-points
Parameter baseline 5 min 15 min 30 min 60 min 120 min 360 min 720 min
HR I 90.00±5.34 82.50±4.53 85.00±6.26
80.00±5.34 80.00±5.34 78.75±6.10 82.50±5.90 92.50±7.50
C 90.00±8.16 85.00±7.18 80.00±8.56 86.66±7.60 78.33±4.77 81.66±5.42 93.33±9.54 88.33±7.03
PR I 0.106±0.007
0.117±0.010 0.117±0.009 0.120±0.008 0.120±0.009 0.117±0.009 0.119±0.008 0.110±0.007
C 0.101±0.005 0.087±0.006 0.095±0.005 0.099±0.004 0.099±0.005 0.100±0.007 0.0091±0.008 0.100±0.005
QRS I 0.093±0.003
0.098±0.003 0.099±0.003 0.095±0.003 0.094±0.003 0.094±0.004 0.094±0.003 0.090±0.004
C 0.954±0.005 0.096±0.005 0.097±0.006 0.098±0.005 0.096±0.003 0.096±0.005 0.099±0.005 0.100±0.004
ST I 0.064±0.019 0.083±0.007 0.075±0.022 0.061±0.021 0.065±0.021 0.087±0.005 0.077±0.009 0.085±0.006C 0.052±0.026 0.033±0.031 0.034±0.031 0.060±0.026 0.031±0.035 0.055±0.027 0.062±0.027 0.060±0.026
QT I 0.273±0.011
0.290±0.011 0.295±0.009 0.288±0.009 0.293±0.014 0.292±0.013 0.292±0.012 0.277±0.009
C 0.272±0.006 0.279±0.005 0.276±0.007 0.275±0.007 0.276±0.006 0.280±0.006 0.274±0.009 0.273±0.007
JT I 0.180±0.009
0.192±0.009 0.196±0.008 0.193±0.007 0.198±0.011 0.197±0.010 0.198±0.009 0.187±0.007
C 0.176±0.009 0.182±0.007 0.178±0.010 0.177±0.009 0.179±0.008 0.184±0.009 0.174±0.009 0.173±0.008
QTc I 0.309±0.008 0.318±0.007
0.322±0.006 0.312±0.008 0.311±0.010 0.314±0.012 0.315±0.009 0.311±0.008
C 0.306±0.007 0.314±0.009 0.301±0.007 0.303±0.008 0.308±0.008 0.311±0.004 0.313±0.006 0.315±0.007
JTc I 0.204±0.007 0.210±0.007 0.213±0.006 0.209±0.005 0.288±0.025 0.211±0.009 0.213±0.007 0.209±0.007C 0.198±0.010 0.205±0.008 0.199±0.011 0.195±0.009 0.199±0.007 0.204±0.008 0.199±0.008 0.198±0.005
TWA I 0.100±0.106 0.007±0.111 0.001±0.111 -0.003±0.104 0.024±0.127 0.044±0.011 0.065±0.119 0.050±0.083C 0.068±0.171 0.219±0.173 0.053±0.207 0.089±0.118 -.034±0.173 0.028±0.175 0.044±0.151 -.004±0.165
HR: heart rate; TWA: T wave amplitude; I: intervention; C: control
*Values shown in bold were significantly different from the baseline value in that group, according to paired samples 
t-test (P<0.05)
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Figure-1 shows the alterations in mean values of 
heart rate, PR interval, QRS duration, ST segment, QT 
interval, JT interval, QTc, and JTc in each of the in-
tervention and control groups and compares the trend 
of changes between the dogs in these two groups.Fig-
ure-2 compares the changes in mean T wave ampli-
tude between the intervention and the control groups. 
The intervention and the control groups showed no 
significant differences in any of the measured param-
eters at any of the time-points.
Regarding the side effects of the treatment, a sec-
ond-degree ventricular block was seen in one dog 
(12.5%) in the intervention group, which is presented 
in Figure-3. In contrast, none of the dogs in the control 

































































































































Figure.1. Comparison of the changes in mean values of some measured parameters over the first twelve hours after the intervention 
between the intervention and the control groups
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Figure.2. Comparison of the changes in mean T wave amplitude between the intervention and the control groups
Figure.3. Second-degree ventricular block in one dog in the intervention group
DISCUSSION
Granisetron has been emerged as a potent anti-
emetic agent with manifold indications in different 
conditions. However, there is not enough evidence 
to draw a firm conclusion on the safety of this drug. 
The present work is one of the few studies investigat-
ing the electrocardiographic safety of this drug and 
probably the first study to investigate this issue in an-
imal models. In this study we only included female 
dogs because female dogs possesses larger potassium 
channels in the epicardium and endocardium, which 
in turn provides a greater repolarization gradient and 
longer QT intervals compared with male dogs (Xiao 
et al. 2006).
We found no significant difference regarding any 
of the measured variables at any of the time-points 
between the intervention and control group. This find-
ing is in line with several other studies comparing the 
cardiac effects of granisetron with placebo among 
healthy adults (Boike et al. 1997; Mason et al. 2013; 
Mason et al. 2012).
Mason and colleagues in a double-blinded ran-
domized placebo-controlled crossover trial on healthy 
subjects compared subcutaneous and intravenous 
granisetron with placebo over a 49-hour period in 
terms of ECG changes. They found no clinically sig-
nificant difference in any of the electrocardiographic 
parameters between granisetron and control groups 
(Mason et al. 2014).
Similarly, Mason et al. in another randomized 
controlled crossover trial, evaluated 12-lead ECGs 
in healthy subjects receiving subcutaneous APF530 
(sustained-release granisetron) and intravenous gran-
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isetron with placebo and found no clinically signifi-
cant difference in electrocardiographic parameters of 
the subjects (Mason et al. 2013).
We also found that in the control group, none of 
the measured parameters changed significantly from 
the baseline at any of the time-points. However, in the 
intervention group, statistically significant changes in 
measured parameters were seen compared with base-
line at some points in the study, including reduced 
heart rate as well as an increase in QRS duration and 
PR, QT, QTc, and JT intervals. However, the changes 
were not clinically significant, with the exception of a 
second-degree ventricular block in the group receiv-
ing granisetron.
In fact, granisetron can potentially affect PR, QT, 
and JT intervals and QRS duration by blocking both 
the sodium and rapid potassium channels. Therefore, 
we can attribute the changes in ECG parameters in 
our study to blockade of sodium and potassium chan-
nels in myocytes, both of which can lead to ventric-
ular dysrhythmias (Jantunen et al. 1996; Kuryshev et 
al. 2000).
As our findings indicate increased QT interval in 
some time-points among the intervention groups, giv-
en that QT interval comprises QT and QRS, we can 
state that both depolarization and repolarization of 
ventricles are affected by granisetron.
Although no previous study has investigated the 
electrocardiographic side effects of granisetron in an-
imal models, our results were comparable to human 
studies on this subject, which reported statistically 
significant changes in parameters of ECG including 
PR interval, QT interval, QRS duration, and QT inter-
val (Boike et al. 1997; Hunt et al. 1995; Schnell 2003; 
Tricco et al. 2016).
Moreover, some studies have reported the electro-
cardiographic effects of ondansetron, another 5-HT3 
receptor antagonist, in animal models. Williams et al. 
reported that ondansetron can increase the QTc inter-
val in a dose-dependent manner in anesthetized dogs. 
They also suggested that this effect could be attribut-
ed to the effects of this drug on potassium channels 
(Williams et al. 1991). In another animal study by 
Ghaffari and colleagues, standard doses of ondanse-
tron were introduced to eight crossbreed dogs and the 
results indicated a significant increase in QT interval 
along with significantly decreased heart rate (Ghaffari 
et al. 2010).
In the present study, we observed a decrease in 
heart rate of dogs in the granisetron group, started 
30 minutes after the intervention and continuing for 
2 hours, though being insignificant. We hypothesize 
that granisetron can decrease the heart rate through 
blocking serotonin receptors on the afferent vagus 
nerve in the gastrointestinal tract and the feedback 
mechanism (Buyukavci et al. 2005; Spartinou et al. 
2017).
Our study had some limitations. One of the lim-
itations was our small sample size, which increases 
the chance of biases. Another limitation was using a 
single dose and only one mode of delivering the drug. 
Evaluating the effects of divided doses during the day 
and other modes of delivery such as subcutaneous 
granisetron could have been of benefit.
Since over 85% of cardiovascular toxicities have 
been predicted by animal studies on dogs, it can be 
posited that there are physiologic proximities be-
tween canine and human species (Gralinski 2003). 
Therefore, our findings can be of cardinal importance 
in directing further human research regarding the car-
diotoxic effects of granisetron by providing several 
useful insights into the safety of this drug when used 
in healthy dogs.
CONCLUSIONS
Our findings indicate that despite granisetron at 
0.5 mg/kg b.w. intravenously can lead to some elec-
trocardiographic changes, which are mostly mild, 
trivial, and clinically insignificant. Therefore, it can 
be said that granisetron has transient and subclinical 
effects on the electrocardiographic parameters.Clini-
cal electrocardiographic manifestations of granisetron 
can thus be possibly seen in patients with history of 
arrhythmia, conductive heart disorders, electrolyte 
disturbances (especially hypokalemia, which can be 
caused by viral gastroenteritis), those receiving car-
diotoxic chemotherapy regimens, or patients with 
physiologic long QT intervals.
AKNOWLEDGMENTS
The authors thank the Vice Chancellor for Re-
search of Ferdowsi University of Mashhad for finan-
cial supports (Protocol Code: 3/ 29801). This article 
is the outcome of DVM student thesis. In addition, the 
authors gratefully appreciate the cooperation of Dr. 
Masoud Rajabioun for his expert technical assistance.
http://epublishing.ekt.gr | e-Publisher: EKT | Downloaded at 23/08/2021 04:41:31 |
J HELLENIC VET MED SOC 2021, 72(1)
ΠΕΚΕ 2021, 72(1)
2701H. GHAEMI, H. SALARI SEDIGH, M. SELK GHAFFARI
REFERENCES
Boike SC, ILson B, Zariffa N, Jorkasky DK (1997) Cardiovascular effects 
of iv granisetron at two administration rates and of ondansetron in 
healthy adults American journal of health-system pharmacy 54:1172-
1176
Buyukavci M, Olgun H, Ceviz N (2005) The effects of ondansetron and 
granisetron on electrocardiography in children receiving chemothera-
py for acute leukemia American journal of clinical oncology 28:201-
204
Cakir F, Yapar O, Canpolat C, Akalin F, Berrak S (2012) Cardiac effects of 
granisetron in a prospective crossover randomized dose comparison 
trial Supportive Care in Cancer 20:2451-2457
Chevallier B (1993) on behalf of the Granisetron Study Group: The con-
trol of acute cisplatin-induced emesis. A comparative study of gran-
isetron and a combination regimen of high-dose metoclopramide and 
dexamethasone Br J Cancer 68:176-180
Coop AJ (2003) Comment: electrocardiographic and cardiovascular ef-
fects of the 5-hydroxytryptamine-3 receptor antagonists Annals of 
Pharmacotherapy 37:1918-1918
Dennis S, Wotton P, Boswood A, Flaherty D (2007) Comparison of the 
effects of thiopentone and propofol on the electrocardiogram of dogs 
The Veterinary Record 160:681-686
Ghaffari MS, Moghaddassi AP, Khorami N (2010) The acute effects of 
ondansetron on the electrocardiogram in clinically normal dogs Com-
parative clinical pathology 19:499-502
Goddard A, Leisewitz AL (2010) Canine parvovirus Veterinary Clinics: 
Small Animal Practice 40:1041-1053
Gomez-de-Segura IA, Grande AG, De Miguel E (1998) Antiemetic effects 
of Lerisetron in radiation-induced emesis in the dog Acta Oncologica 
37:759-763
Gralinski MR (2003) The dog’s role in the preclinical assessment of QT 
interval prolongation Toxicologic pathology 31:11-16
Gregory RE, Ettinger DS (1998) 5-HT3 receptor antagonists for the 
prevention of chemotherapy-induced nausea and vomiting Drugs 
55:173-189
Grunberg SM (1993) Potential for combination therapy with the new anti-
serotonergic agents European Journal of Cancer 29:S39-S41
Harris DG (2010) Nausea and vomiting in advanced cancer British medi-
cal bulletin 96:175-185
Hsu ES (2010) A review of granisetron, 5-hydroxytryptamine3 receptor 
antagonists, and other antiemetics American journal of therapeutics 
17:476-486
Hunt TL, Cramer M, Shah A, Stewart W, Benedict CR, Hahne WF (1995) 
A Double-Blind, Placebo-Controlled, Dose-Ranging Safety Evalua-
tion of Single-Dose Intravenous Dolasetron in Healthy Male Volun-
teers The Journal of Clinical Pharmacology 35:705-712
Janelsins MC, Tejani MA, Kamen C, Peoples AR, Mustian KM, Morrow 
GR (2013) Current pharmacotherapy for chemotherapy-induced nau-
sea and vomiting in cancer patients Expert opinion on pharmacother-
apy 14:757-766
Jantunen IT, Kataja VV, Muhonen TT, Parviainen T (1996) Effects of 
granisetron with doxorubicin or epirubicin on ECG intervals Cancer 
chemotherapy and pharmacology 37:502-504
Keefe DL (2002) The cardiotoxic potential of the 5-HT3 receptor antago-
nist antiemetics: is there cause for concern? The Oncologist 7:65-72
Kuryshev YA, Brown AM, Wang L, Benedict CR, Rampe D (2000) Inter-
actions of the 5-hydroxytryptamine 3 antagonist class of antiemetic 
drugs with human cardiac ion channels Journal of Pharmacology and 
Experimental Therapeutics 295:614-620
Mason J, Moon TE, O’Boyle E, Dietz AJ (2013) Comparison of the effects 
of subcutaneous APF530, intravenous granisetron, moxifloxacin, and 
placebo on the QT interval in humans. American Society of Clinical 
Oncology, 
Mason JW, Moon TE, O’Boyle E, Dietz A (2014) A randomized, place-
bo-controlled, four-period crossover, definitive QT study of the ef-
fects of APF530 exposure, high-dose intravenous granisetron, and 
moxifloxacin on QTc prolongation Cancer management and research 
6:181
Mason JW, Selness DS, Moon TE, O’Mahony B, Donachie P, Howell J 
(2012) Pharmacokinetics and repolarization effects of intravenous 
and transdermal granisetron Clinical Cancer Research 18:2913-2921
Nandi S, Kumar M (2010) Canine parvovirus: current perspective Indian 
Journal of Virology 21:31-44
Navari RM, Koeller JM (2003) Electrocardiographic and cardiovascular 
effects of the 5-hydroxytryptamine3 receptor antagonists Annals of 
Pharmacotherapy 37:1276-1286
Pınarlı F, Elli M, Daǧdemir A, Baysal K, Acar S (2006) Electrocardio-
graphic findings after 5-HT3 receptor antagonists and chemotherapy 
in children with cancer Pediatric blood & cancer 47:567-571
Schnell FM (2003) Chemotherapy-induced nausea and vomiting: the im-
portance of acute antiemetic control The oncologist 8:187-198
Spartinou A, Nyktari V, Papaioannou A (2017) Granisetron: a review 
of pharmacokinetics and clinical experience in chemotherapy in-
duced-nausea and vomiting Expert opinion on drug metabolism & 
toxicology 13:1289-1297
Tricco AC et al. (2016) Comparative safety and effectiveness of sero-
tonin receptor antagonists in patients undergoing chemotherapy: a 
http://epublishing.ekt.gr | e-Publisher: EKT | Downloaded at 23/08/2021 04:41:31 |
J HELLENIC VET MED SOC 2021, 72(1)
ΠΕΚΕ 2021, 72(1)
2702 H. GHAEMI, H. SALARI SEDIGH, M. SELK GHAFFARI
systematic review and network meta-analysis BMC Medicine 14:216 
doi:10.1186/s12916-016-0761-9
Williams PD, Cohen ML, Turk JA (1991) Electrocardiographic effects of 
zatosetron and ondansetron, two 5HT3 receptor antagonists, in anes-
thetized dogs Drug development research 24:277-284
Woods C, Pollock R, Carmichael L (1980) Canine parvoviral enteritis 
Journal of the American Animal Hospital Association 16:171-179
Xiao L, Zhang L, Han W, Wang Z, Nattel S (2006) Sex-based transmural 
differences in cardiac repolarization and ionic-current properties in 
canine left ventricles American Journal of Physiology-Heart and Cir-
culatory Physiology 291:H570-H580
Yamakuni H et al. (2000) Probable Involvement of the 5-Hydroxytrypt-
amine4Receptor in Methotrexate-Induced Delayed Emesis in Dogs 
Journal of Pharmacology and Experimental Therapeutics 292:1002-
1007
Powered by TCPDF (www.tcpdf.org)
http://epublishing.ekt.gr | e-Publisher: EKT | Downloaded at 23/08/2021 04:41:31 |
